DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 22134/S004

SUPPLEMENT APPROVAL

Allergan, Inc.
Attention: Linda McCauley, PhD
Sr. Specialist, US Regulatory Affairs
2525 Dupont Dr.
P. O. Box 19534
Irvine, CA 92623-9534

Dear Dr. McCauley:
Please refer to your Supplemental New Drug Application (sNDA) dated and received April 3, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for LASTACAFT (alcaftadine ophthalmic solution), 0.25%

We acknowledge receipt of your amendments dated May 6 and September 11, 2015.

This "Changes Being Effected" supplemental new drug application provides for the following revisions to the Package Insert (additions are underlined).

1. The 5 WARNINGS AND PRECAUTIONS/5.3 Topical Ophthalmic Use only section is deleted and the corresponding information is relocated in the HIGHLIGHTS of PRESCRIBING INFORMATION, as follows:

   LASTACAFT (alcaftadine ophthalmic solution)
   <u>For Topical Ophthalmic Use</u>

2. The 6 ADVERSE REACTIONS/6.3 Postmarketing Experience subsection is revised as follows:

   6.3 Postmarketing Experience
   The following adverse reactions have been identified during postmarketing use of LASTACAFT® in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions include eye discharge, eye swelling, erythema of eyelid, eyelid edema<u>, lacrimation increased, vision blurred</u>, hypersensitivity <u>reactions including swelling of the face or allergic dermatitis</u>, and somnolence

3. The 12 CLINICAL PHARMACOLOGY/12.3 Pharmacokinetics/Metabolism subsection is revised as follows:

   The metabolism of alcaftadine is mediated by non-CYP450 cytosolic enzymes to the active carboxylic acid metabolite. In vitro studies showed that neither alcaftadine nor the carboxylic acid metabolite substantially inhibited reactions catalyzed by major CYP450 enzymes.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text, which is identical to the package insert submitted on September 11, 2015.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Judit Milstein, Chief, Project Management Staff, at 301-796-0763.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, MD
Deputy Director
Division of Transplant and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S): Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WILEY A CHAMBERS
09/30/2015